Author: Dino Mustafić

January 24, 2025 Off

Medix Biochemica buys German CANDOR Bioscience

By Dino Mustafić

Medix Biochemica, a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, announced the acquisition of CANDOR Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions.

January 17, 2025 Off

RTW Biotech Opportunities Ltd with additional investment in Umoja Biopharma

By Dino Mustafić

RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company has made an additional investment in the Series C financing round of Umoja Biopharma (“Umoja”), a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in oncology and autoimmune treatments.